Literature DB >> 28149751

Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".

Giulio Metro1, Rita Chiari1.   

Abstract

Entities:  

Year:  2016        PMID： 28149751      PMCID： PMC5233885          DOI： 10.21037/tlcr.2016.12.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  8 in total

Review 1.  The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Authors:  Cesare Gridelli; Benjamin Besse; Julie Renee Brahmer; Lucio Crinò; Enriqueta Felip; Filippo de Marinis
Journal:  Clin Lung Cancer       Date:  2016-01-28       Impact factor: 4.785

2.  Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.

Authors:  Giulio Metro; Gianluigi Lunardi; Chiara Bennati; Pietro Chiarini; Isabella Sperduti; Biagio Ricciuti; Luca Marcomigni; Cinzia Costa; Lucio Crinò; Piero Floridi; Stefania Gori; Rita Chiari
Journal:  J Neurooncol       Date:  2016-06-20       Impact factor: 4.130

3.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

4.  Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

Authors:  Rita Chiari; Giulio Metro; Daniela Iacono; Guido Bellezza; Alberto Rebonato; Alessandra Dubini; Isabella Sperduti; Chiara Bennati; Luca Paglialunga; Marco Angelo Burgio; Sara Baglivo; Raffaele Giusti; Vincenzo Minotti; Angelo Delmonte; Lucio Crinò
Journal:  Lung Cancer       Date:  2015-09-14       Impact factor: 5.705

5.  Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.

Authors:  Giulio Metro; Rita Chiari; Biagio Ricciuti; Alberto Rebonato; Marco Lupattelli; Stefania Gori; Chiara Bennati; Corrado Castrioto; Piero Floridi; Vincenzo Minotti; Pietro Chiarini; Lucio Crinò
Journal:  Expert Opin Pharmacother       Date:  2015-10-06       Impact factor: 3.889

6.  Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:  Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.

Authors:  Biagio Ricciuti; Rita Chiari; Pietro Chiarini; Lucio Crinò; Daniele Maiettini; Vienna Ludovini; Giulio Metro
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859
  8 in total
  1 in total

1.  Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.

Authors:  Sara Baglivo; Martina Mandarano; Guido Bellezza; Vincenzo Minotti; Angelo Bonaiti; Matthias J Fischer; Ilaria Birocchi; Fausto Roila; Niccolò Metelli; Vienna Ludovini; Giulio Metro
Journal:  Oncol Ther       Date:  2022-01-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.